Copyright: ©Author(s) 2026.
World J Gastrointest Oncol. Jul 15, 2026; 18(7): 120724
Published online Jul 15, 2026. doi: 10.4251/wjgo.120724
Published online Jul 15, 2026. doi: 10.4251/wjgo.120724
Table 1 Patient demographics and clinical characteristics, n (%)/mean ± SD/median (interquartile range)
| Variables | Overall (n = 958) | Training set (n = 671) | Validation set (n = 287) | P value |
| Age | 57.90 ± 11.45 | 58.14 ± 11.26 | 57.36 ± 11.87 | 0.333 |
| Karnofsky performance status | 82.87 ± 9.18 | 83.17 ± 8.66 | 82.16 ± 10.29 | 0.120 |
| Sex | 0.361 | |||
| Male | 731 (76.30) | 506 (75.41) | 225 (78.40) | |
| Female | 227 (23.70) | 165 (24.59) | 62 (21.60) | |
| Hypertension | 0.698 | |||
| No | 762 (79.54) | 531 (79.14) | 231 (80.49) | |
| Yes | 196 (20.46) | 140 (20.86) | 56 (19.51) | |
| Diabetes | 1.000 | |||
| No | 805 (84.03) | 564 (84.05) | 241 (83.97) | |
| Yes | 153 (15.97) | 107 (15.95) | 46 (16.03) | |
| Body mass index | 0.289 | |||
| 18.5-23.9 | 577 (60.23) | 395 (58.87) | 182 (63.41) | |
| ≥ 24 | 316 (32.99) | 226 (33.68) | 90 (31.36) | |
| < 18.5 | 65 (6.78) | 50 (7.45) | 15 (5.23) | |
| Tumor node metastasis | 0.085 | |||
| I-II | 227 (23.70) | 170 (25.34) | 57 (19.86) | |
| III | 347 (36.22) | 230 (34.28) | 117 (40.77) | |
| IV | 384 (40.08) | 271 (40.39) | 113 (39.37) | |
| Radiotherapy | 0.340 | |||
| No | 877 (91.54) | 610 (90.91) | 267 (93.03) | |
| Yes | 81 (8.46) | 61 (9.09) | 20 (6.97) | |
| Chemotherapy | 0.375 | |||
| No | 609 (63.57) | 420 (62.59) | 189 (65.85) | |
| Yes | 349 (36.43) | 251 (37.41) | 98 (34.15) | |
| Surgery | 0.943 | |||
| No | 307 (32.05) | 216 (32.19) | 91 (31.71) | |
| Yes | 651 (67.95) | 455 (67.81) | 196 (68.29) | |
| Immunotherapy | 0.112 | |||
| No | 853 (89.04) | 605 (90.16) | 248 (86.41) | |
| Yes | 105 (10.96) | 66 (9.84) | 39 (13.59) | |
| Targeted | 0.347 | |||
| No | 650 (67.85) | 462 (68.85) | 188 (65.51) | |
| Yes | 308 (32.15) | 209 (31.15) | 99 (34.49) | |
| White blood cell | 6.61 ± 3.19 | 6.54 ± 3.14 | 6.77 ± 3.28 | 0.311 |
| LYM | 1.22 ± 0.50 | 1.20 ± 0.50 | 1.25 ± 0.52 | 0.142 |
| Albumin | 38.73 ± 6.13 | 38.96 ± 6.08 | 38.20 ± 6.22 | 0.078 |
| Globulin | 32.75 ± 6.75 | 32.66 ± 6.65 | 32.97 ± 6.99 | 0.519 |
| Alpha-fetoprotein | 11.05 (3.20, 334.60) | 12.10 (3.24, 444.70) | 10.40 (3.16, 168.86) | 0.162 |
| Lactic dehydrogenase | 293.78 ± 315.56 | 294.11 ± 256.06 | 292.99 ± 423.80 | 0.960 |
| FIB | 3.33 ± 1.26 | 3.30 ± 1.23 | 3.41 ± 1.33 | 0.205 |
| FIB degradation products | 2.50 (2.50, 5.97) | 2.50 (2.50, 5.80) | 2.70 (2.50, 7.05) | 0.441 |
| β2-microglobulin | 3.10 ± 1.42 | 3.13 ± 1.48 | 3.03 ± 1.27 | 0.338 |
| Neutrophil-to-LYM ratio | 3.50 (2.29, 5.30) | 3.45 (2.30, 5.32) | 3.58 (2.27, 5.20) | 0.965 |
| Platelet-to-LYM ratio | 142.51 (97.36, 200.95) | 143.75 (94.25, 198.86) | 141.94 (102.54, 204.88) | 0.664 |
- Citation: Tan JY, Yang JX, Xu QJ, Zhao YL, Zhang W, Li XS. Prognostic nomogram model for overall survival in patients with hepatocellular carcinoma. World J Gastrointest Oncol 2026; 18(7): 120724
- URL: https://www.wjgnet.com/1948-5204/full/v18/i7/120724.htm
- DOI: https://dx.doi.org/10.4251/wjgo.120724